BioStem Technologies Q3 revenue falls year over year
Overview
US regenerative medicine firm's Q3 revenue fell yr/yr, with hospital revenue up sequentially
Company raised full-year 2026 revenue guidance
Cost reduction plan expected to lower annualized cash operating expenses by $10-$12 mln from 2027
Outlook
BioStem raises 2026 revenue guidance to $28 mln-$29 mln from $26 mln-$29 mln
Company expects in-house production of Neox and Clarix to begin in H1 2027
BioStem finalizing cost reduction plan to cut annualized cash operating expenses by $10 mln-$12 mln, with full benefit in Q1 2027
Result Drivers
CUSTOMER EXPANSION - Co said sequential hospital revenue growth was driven by adding new accounts and deeper penetration with existing customers
HIGHER SUPPLY COSTS - Co said gross margin fell sequentially due to higher pricing under BioTissue supply agreement after discounted pricing expired
OPERATING COST INCREASES - Co said operating expenses rose mainly due to higher general and administrative costs related to uplisting, financing activity, and payroll taxes on RSU vesting
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | $7.64 mln | $7.17 mln (1 Analyst) | |
Q3 Loss Per Share | $0.64 | $0.43 (1 Analyst) | |
Q3 Net Loss | $11.40 mln | $9.45 mln (1 Analyst) |
Analyst Coverage
The one available analyst rating on the shares is "buy"
Wall Street's median 12-month price target for BioStem Technologies, Inc. is $7.00, about 376.2% above its November 11 closing price of $1.47
Reuters Recommended Reads
Nov 12 - EyePoint Pharmaceuticals Q3 revenue falls, net loss widens
Nov 12 - Pelthos Q3 Zelsuvmi revenue jumps 114%, net loss narrows
Nov 12 - Fennec Pharma Q3 product sales rise 56% on PEDMARK demand
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)